Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases

Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases

<p><strong>Background & Aims</strong> Gut-homing lymphocytes that express the integrin α4β7 and CCR9 might contribute to development of primary sclerosing cholangitis (PSC). Vedolizumab, which blocks the integrin α4β7, is used to treat patients with inflammatory bowel disea...

Mô tả đầy đủ

Chi tiết về thư mục
Những tác giả chính:	Lynch, K, Chapman, R, Keshav, S, Montano-Loza, A, Mason, A, Kremer, A, Vetter, M, De Krijger, M, Ponsioen, C, Trivedi, P, Hirschfield, G, Schramm, C, Liu, C, Bowlus, C, Estes, D, Pratt, D, Hedin, C, Bergquist, A, De Vries, A, Janneke Van Der Woude, C, Yu, L, Assis, D, Boyer, J, Ytting, H, Hallibasic, E, Trauner, M, Marschall, H, Daretti, L, Marzioni, M, Yimam, K, Perin, N, Floreani, A, Beretta-Piccoli, B, Rogers, J, International Primary Sclerosing Cholangitis Study Group (IPSCSG), Levy, C
Định dạng:	Journal article
Ngôn ngữ:	English
Được phát hành:	Elsevier 2019

Những quyển sách tương tự

International experience of vedolizumab in primary sclerosing cholangitis and inflammatory bowel disease
Bằng: Williamson, K, et al.
Được phát hành: (2018)

Vedolizumab for the treatment of chronic pouchitis
Bằng: Travis, S, et al.
Được phát hành: (2023)

Fecal calprotectin is an early predictor of endoscopic response and histologic remission after the start of vedolizumab in inflammatory bowel disease
Bằng: Renske W. M. Pauwels, et al.
Được phát hành: (2020-12-01)

Subcutaneous vedolizumab interval extension in inflammatory bowel disease patients: a case series
Bằng: Suzanne I. Anjie, et al.
Được phát hành: (2024-02-01)

Vedolizumab: Potential Mechanisms of Action for Reducing Pathological Inflammation in Inflammatory Bowel Diseases
Bằng: Matthew Luzentales-Simpson, et al.
Được phát hành: (2021-02-01)

P571 Vedolizumab (VDZ) real-world outcomes in ulcerative colitis (UC)
Bằng: Pulusu, S, et al.
Được phát hành: (2018)

Patient considerations in the management of ulcerative colitis – role of vedolizumab
Bằng: Kothari M, et al.
Được phát hành: (2015-08-01)

Vedolizumab for inflammatory bowel diseasesI
Bằng: Igor L. Khalif, et al.
Được phát hành: (2018-08-01)

Vedolizumab in the treatment of inflammatory bowel diseases: whom and how?
Bằng: A. O. Golovenko, et al.
Được phát hành: (2018-10-01)

Vedolizumab as a Potential Culprit in the Development of Ovarian Teratoma?
Bằng: Judy A. Trieu, et al.
Được phát hành: (2017-12-01)

Vedolizumab-Induced Liver Injury
Bằng: Miguel Mascarenhas Saraiva, et al.
Được phát hành: (2020-12-01)

Vedolizumab in paediatric Inflammatory Bowel Disease: A retrospective multi-centre experience From the paediatric IBD Porto Group of ESPGHAN
Bằng: Ledder, O, et al.
Được phát hành: (2017)

Vedolizumab in pediatric inflammatory bowel disease: a retrospective multi-center experience from the Paediatric IBD Porto group of ESPGHAN
Bằng: Ledder, O, et al.
Được phát hành: (2017)

Long-term outcomes and predictors of vedolizumab persistence in ulcerative colitis
Bằng: Beatriz Gros, et al.
Được phát hành: (2024-07-01)

Validation of the prognostic value of histologic scoring systems in primary sclerosing cholangitis: An international cohort study.
Bằng: de Vries, E, et al.
Được phát hành: (2016)

Vedolizumab in Inflammatory Bowel Disease: West versus East
Bằng: Prasanta Debnath, et al.
Được phát hành: (2021-01-01)

Protocol for the development of a core outcome set for clinical trials in primary sclerosing cholangitis
Bằng: Martine Walmsley, et al.
Được phát hành: (2024-06-01)

Post-marketing experience of vedolizumab: Pneumonia and other respiratory tract infections
Bằng: Bhayat, F, et al.
Được phát hành: (2017)

Vedolizumab in Pediatric inflammatory bowel diseases: a retrospective multi-center experience from the paediatric IBD Porto group of ESPGHAN
Bằng: Ledder, O, et al.
Được phát hành: (2017)

Incidence of pneumonia and other respiratory tract infections with vedolizumab treatment: clinical trial experience
Bằng: Feagan, B, et al.
Được phát hành: (2017)

Clinical efficacy of vedolizumab for inflammatory bowel disease
Bằng: Liu Sixue, Zhong Wa, Lin Ying, Xia Zhongsheng, Zhong Yingqiang
Được phát hành: (2022-10-01)

Acute Chest Pain as an Infusion Reaction to Vedolizumab
Bằng: Asaf Levartovsky, et al.
Được phát hành: (2022-06-01)

Post-marketing safety experience of vedolizumab in older patients with inflammatory bowel disease
Bằng: Travis, S, et al.
Được phát hành: (2018)

Respiratory tract infections in patients with inflammatory bowel disease: safety analyses from vedolizumab clinical trials
Bằng: Feagan, BG, et al.
Được phát hành: (2018)

Vedolizumab does not increase risk of clostridium difficile infection in patients with inflammatory bowel disease using vedolizumab: A retrospective cohort study
Bằng: Abdulaziz Saad Alshahrani, et al.
Được phát hành: (2023-09-01)

Impact on the budget of ONLS program of vedolizumab introduction for the treatment of inflammatory bowel disease
Bằng: S. K. Zyryanov, et al.
Được phát hành: (2018-05-01)

Vedolizumab more likely to be discontinued than ustekinumab in anti-TNF-experienced patients with fistulizing Crohn’s disease
Bằng: Kira L. Newman, et al.
Được phát hành: (2023-03-01)

Therapeutic Drug Monitoring of Vedolizumab in Inflammatory Bowel Disease Patients during Maintenance Treatment—TUMMY Study
Bằng: Merve Sivridaş, et al.
Được phát hành: (2023-03-01)

Vedolizumab for perianal fistulizing Crohn’s disease: systematic review and meta-analysis
Bằng: Fares Ayoub, et al.
Được phát hành: (2022-04-01)

Introducing vedolizumab to clinical practice: who, when and how?
Bằng: Bryant, R, et al.
Được phát hành: (2015)

A product review of vedolizumab in inflammatory bowel disease
Bằng: Robert Battat, et al.
Được phát hành: (2019-10-01)

Vedolizumab in the treatment of inflammatory bowel disease: evolving paradigms
Bằng: Benjamin Crooks, et al.
Được phát hành: (2020-03-01)

Incidence of pneumonia and other respiratory tract infections with vedolizumab treatment for inflammatory bowel disease: clinical trial experience
Bằng: Feagan, B, et al.
Được phát hành: (2017)

Evaluating Efficacy of Vedolizumab, Ustekinumab, and Golimumab in the Management of Inflammatory Bowel Disease and the Combined Role of Nutritional Therapy with Biologics: A Review
Bằng: Shahed Kamal, et al.
Được phát hành: (2024-08-01)

Post-marketing experience of vedolizumab in inflammatory bowel disease: analysis of pneumonia and other respiratory tract infections
Bằng: Bhayat, F, et al.
Được phát hành: (2017)

Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease.
Bằng: Bye, W, et al.
Được phát hành: (2017)

Vedolizumab in Crohn Disease genesis-sefh drug evaluation report
Bằng: Jenifer González Chávez, et al.
Được phát hành: (2015-09-01)

Ustekinumab and Vedolizumab Dual Biologic Therapy in the Treatment of Crohn’s Disease
Bằng: Eddie Y. Liu, et al.
Được phát hành: (2017-01-01)

Take vedolizumab home: transition from intravenous to subcutaneous treatment
Bằng: Kaituo Huang, et al.
Được phát hành: (2024-05-01)

Acquired hemophilia associated with vedolizumab in a patient with hemorrhagic rectocolitis
Bằng: Thomas Schiestel
Được phát hành: (2023-03-01)